Background Nonalcoholic fatty liver disease (NAFLD) represents a histological spectrum ranging from benign hepatic steatosis (NAFL) to nonalcoholic steatohepatitis (NASH). NAFLD is closely associated with insulin resistance (IR), and although the role of IR in NAFLD has been an area of intense investigation, there are limited data on pancreatic b-cell function. Aim To evaluate the pancreatic b-cell function in NAFLD using the homeostatic model assessment-b (HOMA-b) and b-cell index (BI). Methods HOMA-b was measured in ninety-nine nondiabetic subjects with histologically confirmed NAFLD and compared to lean (age-and gender-matched) and obese (age-, gender-, and BMI-matched) controls. Using the values from an oral glucose tolerance test, BI was compared in 31 non-diabetic, non-cirrhotic subjects with NASH and gender-and BMI-matched controls. Results The subjects with NAFLD had higher HOMA-b compared to both lean and obese controls (43.1 vs. 9 vs.
Introduction
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of elevated aminotransferases in the USA and encompasses a spectrum of disorders characterized by intrahepatic fat accumulation (simple steatosis or NAFL) to varying degrees of necroinflammatory activity (nonalcoholic steatohepatitis or NASH) [1, 2] . NASH is associated with an increase in all-cause mortality and progression to end-stage liver disease [3, 4] . NASH is closely associated with features of metabolic syndrome, particularly insulin resistance [5, 6] . Even in the absence of overt diabetes, almost all patients with NASH have subclinical insulin resistance and a propensity for developing diabetes [5, 7] .
Progression to diabetes is a complex interplay between insulin resistance, insulin sensitivity, and pancreatic bcell function. A decrease in sensitivity to insulin demands compensation through a proportionate adjustment in insulin secretion by pancreatic b-cell to maintain glucose homeostasis [8] . Therefore, accurate assessment of b-cell function can only be made in the context of insulin sensitivity. Since the functional b-cell mass cannot be directly measured in patients, alternative methods that evaluate b-cell function are used. While clamp and frequent sampling intravenous glucose tolerance tests (FSIVGTTs) are considered to be the gold standard in assessing b-cell function, they are limited by their resource and time-intense nature, making them difficult to implement in larger cohort studies [9, 10] . Therefore, simpler models are used in practice/research based on oral glucose tolerance test (OGTT) and models derived from basal measurements (i.e., homeostasis model assessment or HOMA indexes) [11] [12] [13] . Homeostatic model assessment of b-cell function (HOMA-b) has been used to compare pancreatic b-cell function across different populations. HOMA-b assesses pancreatic b-cell function from basal glucose and insulin concentrations and reflects pancreatic b-cell insulin secretion under nonstimulated conditions [14] . However, since the model relies on fasting serum insulin and glucose concentrations, it does not provide information about the b-cell response to a glucose load. In contrast, the b-cell index (BI) uses values from OGTT to estimate b-cell function in stimulated conditions while accounting for insulin sensitivity and thus provides a dynamic assessment pancreatic b-cell response to glucose [15] . An additional advantage of BI over other indices of pancreatic b-cell function is that BI accounts for b-cell compensatory measures in subjects with impaired glucose tolerance [8, 15, 16] and is a more robust and dynamic measure of pancreatic b-cell function.
The relationship between insulin sensitivity and NAFLD is well established [5] . However, there are a limited number of studies evaluating pancreatic b-cell in NASH [17] [18] [19] [20] . Despite rigorous methodology, these studies are limited by either a small sample size [19, 20] or lack of differentiation between NAFLD and NASH [18] [19] [20] , and the association between all histological parameters of NAFLD and pancreatic b-cell function was not reported [17] [18] [19] [20] . Additionally, these studies were conducted in an Italian cohort, and there are no data regarding pancreatic b-cell function and NAFLD in a North American cohort. Therefore, we hypothesized that NAFLD is associated with a decline in pancreatic b-cell function in a North American cohort. In order to bridge these gaps in knowledge, the present study was designed to: (1) evaluate HOMA-b in non-diabetic subjects with NAFLD compared to lean and obese controls, (2) determine the relationship between the histological severity of NAFLD and HOMA-b, (3) evaluate the BI in patients with histologically confirmed NASH using BMI-matched controls, and (4) determine the effects of individual histological features of NASH on BI.
Methods

Study Design
This was an ancillary study that is part of a larger ongoing study of NAFLD-related outcomes and the factors driving these outcomes at the authors' institution. The institutional review board (IRB) approved the study, and the data were analyzed in its entirety by the investigators who are fully responsible for the data and conclusions. The manuscript was reviewed and approved by all investigators prior to its submission.
The Study Population
The data analysis was done in two separate cohorts of patients with varying histological severity of NAFLD. For the first set of analyses, non-diabetic subjects with histologically proven NAFLD (NAFLD and NASH) were used (cohort 1). NAFLD was defined by consumption of less than 20 grams of alcohol every day and a liver biopsy demonstrating NAFLD [21] . The hepatic histology was assessed, and each histological parameter (steatosis, cytologic ballooning, lobular inflammation, and fibrosis) was quantified in a blinded manner according to the NASH-CRN criteria [22] . Patients with any other known liver diseases were excluded from the study. Similarly, subjects with cirrhosis were excluded since underlying portal hypertension can lead to a shunt effect and therefore impair insulin extraction by the liver. This was done to gain a proof-of-concept study since assessment of pancreatic bcell relies on accurate measurement of peripheral insulin levels, which can be unpredictable in those with cirrhosis or portal hypertension. Subjects with NAFLD were matched 1:1 with the following two controls groups to evaluate the impact of weight on pancreatic b-cell function: (1) lean (age-and gender-matched but BMI \ 25 kg/m 2 ) and (2) obese (age-, gender-, and BMI-matched) controls. The control group consisted of subjects with no known liver disease and normal serum aminotransferase levels (AST/ ALT \ 19 IU/L in women and \30 IU/L in men) [23] . In controls, the presence of underlying hepatic steatosis was additionally ruled out via use of liver fat score, which now has been further validated as a robust marker of detecting NAFLD even when compared to those with HCV [24, 25] . Subjects with known diagnosis of diabetes, fasting blood sugar of [100 mg/dL, use of oral hypoglycemic agents or insulin were excluded from the study. Also, subjects with known chronic kidney disease or elevated serum creatinine were excluded from analysis.
To further study the pancreatic b-cell function, b-cell index (BI) was calculated from oral glucose tolerance test (OGTT). For this part of the study, thirty-one non-diabetic female patients with histologically proven NASH were identified and had a 2-h OGTT (cohort 2). These patients were gender-and BMI-matched with females with no known liver disease and the absence of hepatic fat based on the liver fat score [24] . Patients with histologically confirmed cirrhosis were excluded from this analysis as well.
Study Procedures
Oral Glucose Tolerance Test and Free Fatty Acids (FFAs) in Cohort 2
After a 12-h overnight fast, subjects ingested a solution containing 75 g of dextrose, and venous blood samples were drawn at 0, 30, 60, 90, and 120 min for insulin and glucose measurements. Serum FFAs were drawn at time 0 of the blood samples drawn during the OGTT.
Calculations
As indices of insulin resistance and sensitivity, we used homeostatic model assessment (IR HOMA ) and Matsuda insulin sensitivity index composite (ISIc), respectively [14, 26] . Pancreatic b-cell function was calculated using HOMAb and b-cell index (BI) [14, 15] These parameters of insulin sensitivity and b-cell function were calculated using insulin and glucose values during the OGTT, as follows:
Hepatic fat content was assessed in controls via liver fat score (LFS) [24] 5.
Plan of Analysis
Mean and standard deviations were used to evaluate differences across the groups. Across group, comparisons of continuous variables were performed using one-way analysis of variance (ANOVA) with corrections for multiple comparisons as appropriate for normally distributed variables. A distribution-free test was used for variables that were not normally distributed. Linear regression models were used to evaluate the relationship between laboratory parameters and marker of insulin sensitivity and b-cell function. Spearman's correlation coefficient was used to compare the difference between scores of individual histological parameters and insulin sensitivity and b-cell function. To determine the impact of advanced fibrosis on b-cell function, the cohort with NASH was divided into two groups: (1) low-grade fibrosis (grade 0-2) and (2) high-grade fibrosis (stage 3). Markers of insulin sensitivity and b-cell function were subsequently compared across these two groups. The current study was powered to detect an 80 % difference between controls and study subjects. Power calculation was done using general linear model with repeated measures to calculate observed power. A P value of less than 0.05 was considered significant. All analyses were done in SPSS 21.0 (IBM, Chicago, IL).
Results
For cohort 1, ninety-nine subjects met biopsy criteria and were included in the final analysis. The obese controls were well matched to the NAFLD cohort with respect to age, gender, and BMI (Table 1 ). The lean group was well matched to NAFLD and obese controls with respect to age and gender but had a significantly lower mean BMI (22.4 ± 1.8 vs. 34.9 ± 3.8 vs. 32.5 ± 6 kg/m 2 ; P \ 0.01). The serum AST and ALT levels were significantly elevated in subjects with NAFLD compared to both lean and obese controls (P \ 0.01 NAFLD vs. both controls). The liver fat scores in the lean and obese controls were -2.55 ± 0.65 Dig Dis Sci (2015) 60:2529-2537 2531
and -2.08 ± 0.68, respectively, minimizing the possibility of undiagnosed hepatic steatosis [24] .
NAFLD Is Associated with Overburdened Pancreatic b-Cell in Cohort 1
The serum glucose concentrations were similar across the three groups (Table 1) . Serum insulin levels increased in stepwise manner from lean to obese to subjects with NAFLD (6.8 ± 5 to 12.0 ± 10.9 to 24.9 ± 19.9 uU/mL, respectively; P \ 0.001). Adipose tissue insulin resistance (adipoIR) and serum free fatty acid (FFA) levels were similar between the lean and obese control groups but lower compared to subjects with NAFLD (adipoIR: 4.14 ± 3.5 vs. 6.8 ± 6.3 vs. 19.1 ± 15.8; P \ 0.01 controls vs. NAFLD and FFA: 0.59 ± 0.23 vs. 0.63 ± 0.27 vs. 0.76 ± 0.23; P \ 0.01 controls vs. NAFLD) [27] .
There was a stepwise increase in HOMA-b from lean to obese to subjects with NAFLD (9.1 ± 6.7 % vs. 22.1 ± 26.7 % vs. 43.1 ± 45.9, respectively; P \ 0.01 for all comparisons) (Fig. 1a) . Lean male subjects had a mild increase in HOMA-b compared to female subjects, but otherwise there were no differences in obese controls and subjects with NAFLD with respect to gender (Fig. 1b) . In subjects with NAFLD, HOMA-b was directly related to serum alkaline phosphate (b = 3.71 ± 1.21; P \ 0.01), total bilirubin (b = 175.35 ± 87.6; P = 0.048), and weight (b = 1.60 ± 0.38; P \ 0.01) and indirectly related to age (b = -5.19 ± 1.86; P \ 0.01). In multivariable regression analysis, age (b = -9.23 ± 3.29; P \ 0.01), alkaline phosphatase (b = 3.45 ± 1.11; P \ 0.01), and weight (b = 2.30 ± 0.63; P \ 0.01) remained independently associated with HOMA-b. 
Impact of Histology on HOMA-b
Forty-one subjects had benign hepatic steatosis (NAFL), while fifty-eight had nonalcoholic steatohepatitis (NASH). HOMA-b was similar between subjects with NAFL and NASH (43 ± 8 vs. 43 ± 5.5 %, respectively, P = N.S.) (Fig. 2a) . In univariate analysis in subjects with NAFL, HOMA-b was independently associated with total bilirubin (R = 0.312, P = 0.047), triglycerides (R = 0.55, P \ 0.001), weight (R = 0.529, P \ 0.001), and waist circumference (R = 0.325, P = 0.041). In subjects with NASH, increase in serum free fatty acid concentration was inversely associated with HOMA-b (R = -0.632, P \ 0.001).
There was a trend toward a decrease in HOMA-b in patients with NAFL and NASH with increasing steatosis grade; however, this did not reach statistical significance (Fig. 2b) . In subjects with NASH, bridging fibrosis was associated with an increase in HOMA-b compared to those without advanced fibrosis (58 ± 47 vs. 36 ± 36 %, P = 0.05) (Fig. 2c) . Cytologic ballooning or lobular inflammation did not impact HOMA-b in either subjects with NAFL or NASH.
Evaluation of b-Cell Index in Patients with NASH Using OGTT in Cohort 2
In cohort 2, thirty-one subjects with histologically diagnosed with NASH, along with BMI-and gender-matched controls, had 2-h OGTT performed to assess BI. Metabolically the two groups were similar in regard to the mean BMI, blood pressure, serum HDL, and presence of Table 2 ). The control group was younger (25.7 ± 4.0 vs. 53.5 ± 10.2 years, P \ 0.001) and had lower serum alanine aminotransferase (ALT) levels (16.8 ± 3.8 vs. 94.7 ± 67.6 IU/L P \ 0.0001). The liver fat score of -3.009 ± 0.783 made the presence of hepatic steatosis in the control group unlikely. Although serum glucose concentrations were similar between the two cohorts, patients with NASH had greater than a threefold increase in serum insulin concentrations (6.34 ± 4.13 vs. 21.12 ± 14.86 uU/L, P \ 0.0001). Patients with NASH had worse insulin sensitivity as assessed by Matsuda insulin sensitivity index (ISIc) and IR HOMA (Fig. 3a) . In patients with NASH, IR HOMA was inversely related to serum FFA levels (R = -0.465, P = 0.013).
The b-cell index (BI), a measure of pancreatic b-cell function, was significantly lower in subjects with NASH compared to controls (7.74 ± 25.12 in controls vs. 2.09 ± 1.64 in patients with NASH, P = 0.048) (Fig. 3b) . In patients with NASH, BI values further inversely correlated with serum ALT (R = -0.355, P = 0.049) and age (R = -0.480, P = 0.006). Using general linear models with repeated measures, the observed power was noted to be 0.81.
Compared to those with low-grade lobular inflammation (stage 0-1), subjects with high-grade lobular inflammation (stage 2-3) had lower BI (1.76 ± 1.21 vs. 2.33 ± 1.89), but this did not reach statistical significance. Similarly, increase in steatotic grade was associated with a trend for a decline in BI (stage 1: 2.34 ± 1.53, stage 2 = 2.16 ± 1.88, and stage 3 = 1.46 ± 0.68; P = N.S.) (Fig. 3c ). In subjects with NASH, increase in fibrotic grade was associated with a decline in BI (R = -0.504, P = 0.004). The association between BI and fibrosis stage was independent of patient age, BMI, FFA, and serum ALT levels. Increased fibrosis (fibrotic stage 2-3) was associated with a decrease in BI from 2.92 ± 1.92 to 1.41 ± 0.98 (P = 0.008) (Fig. 3d) and an increase in HOMA-b from 15.2 ± 39.8 to 54.3 ± 47.2 % (P = 0.032) (Fig. 3e) . Similarly, those with higher grade of fibrosis had worse insulin resistance.
Discussion
NAFLD is the hepatic manifestation of the metabolic syndrome and is closely associated with insulin resistance [5, 6] . In the current study, we examined the relationship between pancreatic b-cell function as measured by two separate indices (HOMA-b and BI) in NAFLD. Although HOMA-b is easier to measure, it only reflects pancreatic bcell function in non-stimulated conditions. Therefore, to accurately assess b-cell function under simulated conditions, we used BI, a robust way of modeling pancreatic bcell function under simulated conditions using OGTT [15] . We were highly selective in our patient selection and excluded all subjects with cirrhosis to avoid unpredictable hepatic extraction of insulin in those with cirrhosis due to portosystemic shunting. Since features of the metabolic syndrome are closely associated with pancreatic b-cell dysfunction, we studied b-cell dysfunction in NAFLD in the setting of a metabolically similar control cohort. A key finding in our study is that non-diabetic subjects with NAFLD have significant pancreatic b-cell dysfunction compared to controls. We showed that NAFLD is associated with an exaggerated pancreatic b-cell response, as evident by increased HOMA-b. Although obesity, age, and persistent hyperglycemia have been associated with deterioration in pancreatic b-cell function [28, 29] , the changes observed in HOMA-b in NAFLD were independent of BMI, age, and gender. The increase in pancreatic b-cell secretion of insulin as measured by HOMA-b likely reflects deterioration of insulin sensitivity, resulting in higher insulin demand to maintain euglycemia. This observation was further confirmed with a decline in b-cell index, which reflects both pancreatic b-cell function in the setting of underlying insulin resistance under stimulated conditions. These data coupled with the prior study in an Italian cohort provide a potential pathophysiological explanation of high prevalence of diabetes in NAFLD [30] [31] [32] . Due to the close relationship between insulin resistance and NAFLD, multiple studies have evaluated the role of insulin-sensitizing agents in NAFLD. Accumulating data does not support the use of insulin-sensitizing agents in NAFLD due to lack of long-term efficacy [33] . A speculative explanation for these findings might be that despite improvement in insulin sensitivity, pancreatic b-cell function continues to deteriorate, and additional studies are needed to evaluate how changes in b-cell function impact histology over time. Although no differences were observed between NAFL and NASH in regard to HOMA-b, this may reflect patient selection since all patients with either diabetes or impaired glucose tolerance were excluded from the analysis. Additionally, there was a stepwise decline in HOMA-b in subjects with both NAFL and NASH with increasing steatosis grade (Fig. 2b) . This decrease could be due to either a decrease in pancreatic b-cell function and secretion heralding pancreatic b-cell exhaustion or simply better insulin sensitivity in subjects with steatosis grade 1 compared to grade 3. Additional well-planned long-term prospective studies are necessary to further examine the evolving relationship between steatosis grade and pancreatic b-cell function.
Insulin resistance is an independent predictor of advanced fibrosis in patients with NAFLD [34] . The current study builds on this concept and shows that advanced fibrosis was associated with worse insulin sensitivity (Fig. 3a) , increased demand on pancreatic b-cell for insulin secretion, and impaired pancreatic b-cell function (Fig. 3c) . Surprisingly, the BI was not related to cytologic ballooning, a key histological feature of NASH. A possible explanation for this is the relative homogeneity of the study population. Only 6.5 % of the NASH cohort did not have cytologic ballooning, and therefore, it is difficult to make a statistical correlation with such small numbers. Although this study provides an important proof-of-concept study, additional studies with larger sample size are necessary to build on the findings of the current study to evaluate pancreatic b-cell function in a histologically diverse patient population that ranges from simple hepatic steatosis to NASH to those with bridging fibrosis.
Potential limitations of this study are related to the inherent design of retrospective and cross-sectional studies where we are unable to determine the longitudinal relationship between NAFLD, its histological parameters, and pancreatic b-cell over time. The current study only evaluated BI in female subjects, and therefore, it is unclear whether these data can be generalized to males. Another limitation of the study is that we did not employ frequent sampling of intravenous glucose tolerance test (FSIVGTT) to measure pancreatic b-cell function. However, the BI is a well-validated and well-established model for assessing pancreatic b-cell function and, unlike FSIVGTT, can be done readily and inexpensively in clinical trials to assess bcell function. Finally, we did not use C-peptide-derived indices of b-cell function; however, by excluding all patients with underlying cirrhosis, we minimized the impact of portosystemic shunting on hepatic insulin extraction.
In conclusion, our study is the first to report on pancreatic b-cell dysfunction in non-diabetic subjects with NAFLD in a North American cohort. We also show the impact of histological features of NAFLD, particularly fibrosis on b-cell function in NAFLD. Although larger longitudinal studies are needed to evaluate the impact of pancreatic b-cell function in NAFLD over time, our data confirm the close association between NAFLD and b-cell dysfunction.
